A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Autor: Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kris, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip NVeeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart, Elizabeth Matthews Brunt, Maria Buti, Steve Caldwell, Rotonya Carr, Teresa Casanovas, Laurent Castera, Cyrielle Caussy, Eira Cerda, Naga Chalasani, Wah Kheong Chan, Phunchai Charatcharoenwitthaya, Michael Charlton, Amanda Cheung, Daniela Chiodi, Ray Chung, David Cohen, Kathleen Corey, Helma P Cotrim, Javier Crespo, Anuradha Dassanayake, Nicholas Davidson, Robert De Knegt, Victor De Ledinghen, Münevver Demir, Sebastian Diaz, Anna Mae Diehl, Bruce Dimmig, Melisa Dirchwolf, Ajay Duseja, Karel Dvorak, Mattias Ekstedt, Reda El Wakil, María Lucía Ferraz, Scott Friedman, Michael Fuchs, Amalia Gastaldelli, Anja Geerts, Andreas Geier, Marcos Girala, George Goh, Nicolas Goossens, Isabel Graupera, Hannes Hagström, Zachary Henry, Bela Hunyady, Alan Hutchison, Scott Isaacs, François Jornayvaz, Cynthia Kemp, Denise Kile, Won Kim, David Kleiner, Rohit Kohli, Marcelo Kugelmas, Joel Lavine, Mariana Lazo, Nathalie Leite, Adelina Lozano, Panu Luukkonen, Paula Macedo, Dina Mansour, Christos Mantzoros, Giulio Marchesini, Sebastián Marciano, Kim Martinez, Lyudmila Vladimirova Mateva, Jose M Mato, Alexis McCary, Luca Miele, Ivana Mikolasevic, Veronica Miller, Rosalba Moreno, Cynthia Moylan, Atsushi Nakajima, Jean Charles Nault, Suzanne Norris, Mazen Noureddin, C P Oliveira, Arlin Ong, Martín Padilla, Raluca Pais, Arturo Panduro, Manas K Panigrahi, George Papatheodoridis, Serena Pelusi, Marlene Pérez, Juanita Perez Escobar, Gianluca Perseghin, Mario Pessoa, Salvatore Petta, Massimo Pinzani, Monica Platon Lupsor, Atoosa Rabiee, Stefano Romeo, Yaron Rotman, Ian Rowe, Riina Salupere, Sanjaya Satapathy, Jörn M Schattenberg, Wendy Schaufert, Bernd Schnabl, Lynn Seim, Lawrence Serfaty, David Shapiro, Ashwani K Singal, Lubomir Skladany, Norbert Stefan, Jonathan Stine, Shikha Sundaram, Gianluca Svegliati-Baroni, Gyonzgi Szabo, Frank Tacke, Tawesak Tanwandee, Giovanni Targher, Norah Terrault, Brent Tetri, Maja Thiele, Baron Tisthammer, Aldo Torre Delgadillo, Michael Trauner, Emmanuel Tsochatzis, Laurens Van Kleef, Saskia Van Mil, Lisa VanWagner, Jose Antonio Velarde Ruiz Velasco, Mette Vesterhus, Eduardo Vilar-Gomez, Kymberly Watt, Julia Wattacheril, Fonda Wilkins, José Willemse, Amany Zekry, Shira Zelber-Sagi

Unlabelled: The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::46418370daea859f4048fa40b1946c5a
https://hdl.handle.net/10281/427298

A research agenda for curing chronic hepatitis B virus infection

Autor: Raymond F. Schinazi, Jake Liang, Jordan J. Feld, Jianming Hu, Robert G. Gish, Peter Revill, Anand Mehta, Anna S. Lok, Fabien Zoulim, Jo Ann Rinaudo, Jeffrey S. Glenn, Chari Cohen, John E. Tavis, Francis V. Chisari, Kris V. Kowdley, Wenhui Li, Charles M. Rice, Stephan Locarnini, Harvey J. Alter, Christoph Seeger, Haitao Guo, Kyong-Mi Chang, Pei-Jer Chen, Ju-Tao Guo, Hashem B. El-Serag, Nathaniel A. Brown, Carol L. Brosgart, Kirty Shetty, Timothy M. Block, Alan Brownstein, Tim F. Greten, Brian J. McMahon, Robert P. Perrillo, William S. Mason, Yujin Hoshida

Publikováno v: Hepatology (Baltimore, Md.)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0da5d1c3f0200625e53ccbd9f2c3c13
https://doi.org/10.1002/hep.29509

Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation

Autor: Pedro Goicochea, Oliver Lenz, Eric F. Donaldson, Timothy M. Block, Marion G. Peters, Poonam Mishra, Veronica Miller, Seng Gee Lim, Jonathan Liu, Carol L. Brosgart, Ed G. Marins

Publikováno v: Journal of Virus Eradication
Journal of Virus Eradication, Vol 3, Iss 1, Pp 1-6 (2017)

Hepatitis B infection remains a significant disease burden around the world, with an estimated two billion individuals infected and 350 million living with chronic hepatitis B. Current antivirals are efficacious, but require lifelong treatment for th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecac240e6ec873e2e7e9472b00a93f67
https://pubmed.ncbi.nlm.nih.gov/28275452

Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance

Autor: Bernard Willems, Hie-Won Hann, Lynn D. Condreay, Nancy Leung, Stephen D. Gardner, Mary Woessner, Eugene R. Schiff, David Mutimer, William M. Lee, Carol L. Brosgart, Susan Dixon, Robert P. Perrillo

Publikováno v: Hepatology International. 5:654-663

We and others have reported that adding adefovir dipivoxil (adefovir) to lamivudine results in virological and biochemical improvement in cases of lamivudine resistance. The current study assessed the efficacy and safety of combined therapy after 104

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52ee96b0a48865a5b50aacc4b5c2fd91
https://doi.org/10.1007/s12072-010-9228-9

Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States

Autor: Kris V. Kowdley, Chari Cohen, Robert G. Gish, Michael Ninburg, Lorren Sandt, Ryan Clary, Joan M. Block, Loc T. Le, Timothy M. Block, Carol L. Brosgart

Publikováno v: Hepatology (Baltimore, Md.)

Data from the 2003-2010 National Health and Nutrition Examination Survey (NHANES) indicate that about 3.6 million people in the United States have antibodies to the hepatitis C virus, of whom 2.7 million are currently infected. NHANES, however, exclu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eebeec1f4ec4c573120ba1811d93f236
https://pubmed.ncbi.nlm.nih.gov/26171595